Drug profile · INN
brexpiprazole
RXULTI
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
brexpiprazole (RXULTI) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN brexpiprazole
Brand RXULTI
Route ORAL
Formulation TABLET
ATC code N05AX16
Originator Amneal Pharma Europe Ltd
Frequently asked questions
What is brexpiprazole?
brexpiprazole (RXULTI) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for brexpiprazole?
RXULTI is a marketed brand name for brexpiprazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brexpiprazole?
brexpiprazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.